Optical and space-based networks are becoming central to UK connectivity R&D because future digital infrastructure will need to combine fibre, advanced wireless, satellite, private networks and secure data transmission. For businesses, this creates new grant and R&D tax opportunities, but only where projects are technically ambitious, well evidenced and commercially credible.
The UK’s future connectivity agenda is moving beyond simple coverage targets. The harder task is building networks that are resilient, low-latency, secure, energy-conscious and capable of supporting advanced manufacturing, transport, logistics, defence, healthcare, AI, robotics and rural connectivity.
Optical and space-based networks are communications systems that use light-based transmission, fibre infrastructure, photonics, satellites or high-altitude platforms to move data across terrestrial and non-terrestrial environments.
In practice, the term covers a broad set of technologies. Optical networks include fibre backbone systems, optical switching, photonic components, high-capacity data transport and, in some cases, quantum-secure communication links. Space-based networks include low earth orbit satellites, geostationary satellites, satellite backhaul, direct-to-device communications and hybrid satellite-terrestrial systems.
Optical and space-based networks are connectivity systems that use fibre, photonics, satellites or airborne infrastructure to provide high-capacity, resilient or hard-to-reach communications across land, sea, air and space.
For R&D-led companies, the commercial opportunity is not limited to telecoms operators. It extends to semiconductor design, antenna systems, cybersecurity, edge computing, autonomous transport, aerospace, satellite services, IoT platforms, network orchestration and software-defined infrastructure.
UK connectivity R&D is moving towards integrated networks because future use cases will need more than standard mobile coverage. Industrial systems, autonomous platforms and remote assets require stronger performance, resilience and security.
The UK Wireless Infrastructure Strategy identifies advanced wireless connectivity as a foundation for future sectors and public services. It also recognises that satellite and non-terrestrial networks are becoming part of the connectivity mix, particularly for remote areas, backhaul, IoT and direct-to-device services.
This shift is being driven by four pressures:
For CFOs and CEOs, the point is practical. Connectivity R&D is becoming a board-level infrastructure issue because it affects operational resilience, market access, automation, cybersecurity and future product capability.
The strongest R&D opportunities sit where connectivity performance creates a technical bottleneck. This includes bandwidth, latency, resilience, interoperability, energy efficiency, security and operation in difficult physical environments.
Companies may be carrying out eligible R&D where they are trying to overcome technological uncertainty in areas such as:
Not every connectivity upgrade will qualify as R&D. Routine deployment, standard integration and commercial roll-out activity are unlikely to be enough on their own. The stronger R&D case usually appears where the company is developing or materially improving a technology, architecture, product or process beyond readily available knowledge.
Grants can support connectivity R&D where the project aligns with public priorities such as future telecoms, 6G, rural coverage, space applications, secure networks, transport infrastructure or industrial productivity.
Relevant funding routes may include Innovate UK competitions, UKRI-backed future telecoms research, European Space Agency opportunities, Horizon Europe, Eurostars, defence innovation funding and sector-specific demonstrator programmes.
Grant assessors will usually expect more than a strong technical idea. They need to see a fundable project with clear additionality, work packages, partner roles, exploitation logic and measurable impact.
Grant-fit checklist for connectivity projects
R&D tax relief may apply where a company is seeking to resolve scientific or technological uncertainty in connectivity systems, software, hardware, network design, integration or testing.
The issue is not whether the business works in telecoms or space. The issue is whether the project seeks an advance in science or technology, and whether competent professionals could not readily deduce the solution.
Potentially relevant R&D tax areas include:
For finance teams, evidence quality is essential. Claims should not rely on broad descriptions such as “network improvement” or “digital transformation”. The technical narrative needs to identify the baseline, the uncertainty, the work performed and the outcome.
CFOs and CEOs should watch the gap between technical ambition and funding evidence. Connectivity projects can be capital-intensive, multi-partner and difficult to document if governance is not set up early.
There are several common risks:
The finance team should be involved before a competition opens or a claim period closes. This improves the evidence trail and avoids late-stage reconstruction of technical and cost information.
Optical, satellite and integrated network R&D are related but not interchangeable. Each has different technical uncertainties, funding routes and evidence requirements.
| R&D area | Typical technical focus | Possible funding route | Evidence priority |
| Optical networks | Photonics, fibre performance, optical switching, secure transmission | UKRI, Innovate UK, Horizon Europe, R&D tax relief | Baseline performance, uncertainty, test results |
| Space-based networks | LEO/GEO connectivity, terminals, antennas, satellite backhaul | ESA, Innovate UK, UK Space Agency-linked opportunities, R&D tax relief | Operating environment, integration challenge, deployment case |
| Integrated networks | Hybrid satellite-terrestrial systems, orchestration, edge computing, cybersecurity | Future telecoms, 6G, defence and digital infrastructure funding | Architecture rationale, interoperability, security and latency evidence |
Connectivity R&D is inherently international because standards, spectrum, supply chains, satellites and telecoms equipment markets do not stop at national borders.
The UK is trying to shape future telecoms and 6G standards while also supporting secure, resilient and diversified networks. At the same time, European programmes continue to fund digital, space and advanced connectivity projects, while global satellite operators and equipment suppliers compete for market position.
For UK businesses, this creates both opportunity and complexity. A project may involve UK-based R&D, European partners, overseas subcontractors, ESA support, Horizon Europe collaboration, international customers and group-level IP strategy.
FI Group by EPSA’s global reach and local expertise is relevant for companies managing this complexity. The value is not only identifying one funding route, but understanding how UK R&D tax relief, UK grants, European funding and overseas incentives interact across the project lifecycle.
A good funding-ready connectivity project has a clear technical advance, a defensible cost model, a realistic deployment route and evidence that the work could not be achieved through routine engineering alone.
A strong project pack should include:
For businesses working in optical, satellite or hybrid connectivity, this preparation can reduce wasted bid effort and improve the quality of future R&D tax documentation.
Optical and space-based networks are communications systems that use fibre, photonics, satellites or airborne infrastructure to transmit data. They can support high-capacity, resilient and hard-to-reach connectivity across terrestrial and non-terrestrial environments.
They are important because future industries need resilient, secure and high-performance connectivity. This includes advanced manufacturing, transport, logistics, defence, rural connectivity, AI systems, offshore assets and autonomous platforms.
They can qualify where the business is seeking to resolve scientific or technological uncertainty. Routine deployment or standard configuration is unlikely to be enough, but developing new terminals, protocols, integration methods or performance improvements may be relevant.
Potential routes include Innovate UK, UKRI, European Space Agency programmes, Horizon Europe, Eurostars, defence innovation funding and sector-specific demonstrator competitions. Fit depends on project stage, technology readiness level, partners, costs and public benefit.
Businesses should keep technical baselines, uncertainty statements, design records, test results, failed approaches, cost evidence and staff or subcontractor records. The claim should show why the work was not routine engineering.
No. Standard fibre upgrades, deployment or capacity expansion are not automatically R&D. The project needs to involve an advance in science or technology and uncertainty that competent professionals could not readily resolve.
Connectivity projects often involve significant costs, partners, subcontractors and overlapping funding routes. Early planning helps separate grant-funded and privately funded work, improve evidence quality and reduce compliance risk.
FI Group by EPSA can help assess grant fit, prepare funding applications, review R&D tax eligibility, structure evidence and connect UK projects with relevant international funding routes where appropriate
Regional innovation funding is becoming more locally directed, with regional leaders expected to play a larger role in shaping how public R&D investment supports jobs, business growth and local economic strengths. For UK businesses, this could change how grant strategies are planned, evidenced and aligned with regional priorities.
For CFOs, CEOs and innovation leads, the message is clear: grant funding is no longer only about having a technically strong project. Businesses increasingly need to show how their innovation fits a wider local economic plan, supports sector clusters and creates credible commercial outcomes.
Regional innovation funding is public support designed to help local areas strengthen research, development and commercialisation activity. It can support projects linked to local sector strengths, skills, infrastructure, technology adoption and business-led innovation.
Unlike national grant competitions that apply the same broad criteria across the UK, regional innovation funding often gives greater weight to local economic priorities. This can include advanced manufacturing in one region, life sciences in another, clean energy in another, or digital infrastructure where local capability already exists.
For businesses, this means funding strategy needs to answer two questions at the same time:
This second question is becoming more important. A strong application may need to show why the project belongs in a specific place, how it uses local assets and how it could support jobs, supply chains or business productivity in that area.
The UK is trying to connect R&D investment more closely to regional economic growth. Giving local and regional leaders more influence over innovation funding is intended to help areas back projects that match their existing strengths and growth plans.
This matters because innovation does not happen evenly across the country. Some regions have strong university research bases but weaker commercialisation routes. Others have deep industrial capability but need more support to adopt new technologies, attract investment or build specialist skills.
A more localised approach could help funding decisions reflect:
For companies, the opportunity is useful but more demanding. A business may need to position its innovation as part of a regional growth story, not simply as an internal R&D project.
UK businesses may need to make grant applications more place-specific. Funders could expect clearer evidence that a project supports regional economic objectives, not only company-level growth.
This does not mean technical quality becomes less important. A weak project will not become fundable because it is locally aligned. However, a technically strong project may perform better if it also shows a clear link to the region’s priorities.
For example, a manufacturer developing automation technology in a region with an advanced manufacturing strategy may need to show how the project supports productivity, supplier resilience or local technical capability. A life sciences company near a university cluster may need to explain how collaboration, clinical validation or local talent will support the route to market.
The strongest applications are likely to combine:
CFOs and CEOs should treat regional innovation funding as part of a broader non-dilutive funding strategy, not as a one-off grant opportunity. The key task is to map business projects against both national funding routes and regional priorities.
For leadership teams, this creates a governance question. Innovation funding decisions should sit close to financial planning, capital allocation and technical roadmapping. A company that waits until a grant opens may struggle to produce the evidence, partnerships and cost model needed in time.
A more resilient approach is to maintain a live funding roadmap. This should identify which projects could fit regional funding, Innovate UK competitions, UKRI-backed opportunities, Horizon Europe calls, R&D tax relief and other forms of innovation finance.
Action |
Why it matters |
| Map your R&D pipeline by region | Helps identify which projects align with local economic priorities |
| Review local sector strategies | Supports stronger evidence of regional fit |
| Build partnerships early | Regional funding often rewards credible collaboration |
| Prepare project costs in advance | Reduces rushed budgeting when competitions open |
| Align grants with R&D tax planning | Helps avoid duplication, weak evidence and fragmented funding decisions |
| Track regional policy updates | Funding priorities can shift as local leaders gain more influence |
Sectors with strong regional clusters are likely to benefit most from localised innovation funding. This includes industries where local supply chains, infrastructure or research assets already support growth.
Likely areas of interest include:
The opportunity will vary by region. A clean energy company in Scotland, a battery supply chain business in the Midlands, a medtech company in Cambridge or a digital infrastructure business in the North West may each need a different funding case.
The common point is that regional context now matters. Businesses should be ready to explain why the location strengthens the project and why the project strengthens the location.
Grant applications may need stronger local economic evidence. Businesses should expect more emphasis on regional partnerships, local job creation, supply chain value and alignment with local innovation strategies.
This changes how applications should be written. Generic claims about growth, innovation or economic impact are unlikely to be enough. A stronger application will show:
This is where many businesses underprepare. They focus heavily on the technology and leave the economic case too broad. A project may be innovative, but funders need to understand why it should receive public funding and why the proposed location is credible.
Regional innovation funding and R&D tax relief can support the same wider innovation strategy, but they are not the same mechanism. Grants usually fund defined future work, while R&D tax relief supports qualifying expenditure on eligible R&D activities.
For CFOs, the challenge is coordination. A business that receives grant funding may need to consider how that grant interacts with R&D tax relief, especially where subsidised expenditure, project funding rules or scheme eligibility are relevant.
Good governance matters because poor coordination can create problems later. Businesses should keep clear records of:
A joined-up approach helps reduce duplication, improves auditability and gives finance teams a clearer view of the company’s total innovation funding position.
Businesses should prepare a regional funding evidence pack before a competition opens. This should include project rationale, technical work packages, regional alignment, partner roles, cost assumptions and expected economic outcomes.
A practical pack might include:
This preparation reduces the risk of rushing an application in the final week. It also helps leadership teams decide which competitions are worth pursuing and which are a poor fit.
Regional innovation funding works best when local execution is connected to a wider commercial strategy. For international businesses, UK regional funding can support local delivery while fitting into broader group-level R&D and investment plans.
This is especially relevant for companies operating across multiple jurisdictions. A business may be running R&D in the UK, manufacturing in Europe, commercialisation in North America and supply chain activity across several markets. Funding decisions need to account for that complexity.
FI Group by EPSA supports businesses with this type of cross-border innovation planning. The value is not only identifying a grant. It is understanding how UK regional funding, national R&D incentives and international support mechanisms fit together without creating unnecessary compliance, reporting or cost-allocation issues.
For CFOs and group executives, this matters because funding strategy must be scalable. A local grant can support a project, but the wider value comes from building a repeatable framework for funding, evidence and delivery across markets.
A good regional funding strategy starts with the business plan, not the grant deadline. It identifies which projects deserve external funding support, which regions are strategically relevant and which evidence is needed before applications open.
Good strategy usually includes:
This approach helps businesses avoid low-probability applications. It also protects internal teams from spending time on competitions that look attractive but do not match the project’s stage, location, sector or funding need.
Regional innovation funding is public funding aimed at supporting R&D, commercialisation and innovation-led growth in specific local areas. It usually focuses on regional strengths, local jobs, business productivity and collaboration between companies, universities, research bodies and public-sector partners.
It matters because more funding decisions may be shaped by local economic priorities. Businesses may need to show how their projects support regional growth, not just company-level innovation. This can affect grant strategy, partnership planning and evidence requirements.
A business can improve its chances by aligning its project with local priorities, preparing a clear commercial case, building credible partnerships and showing why public funding is needed. Strong applications connect technical innovation with measurable regional benefit.
Not always. Some programmes may focus on SMEs, while others may allow larger businesses, universities, research organisations or consortia to participate. Eligibility depends on the specific fund, so businesses should check scheme rules before committing time to an application.
Innovate UK grants are often national competitions with defined technology or policy themes. Regional innovation funding may place more emphasis on local economic strategies, regional clusters and place-based impact. Some opportunities may involve both national bodies and local decision-makers.
In some cases, a business may use both grant funding and R&D tax relief as part of its wider innovation funding strategy. However, the interaction can be complex. Companies should assess how grant-funded expenditure affects R&D tax eligibility and documentation.
Funders usually expect to see a clear project plan, credible costs, technical rationale, market need, delivery capability and evidence of economic impact. For regional funding, they may also expect evidence of local alignment, partner involvement and regional benefit.
No. Businesses should prepare project summaries, cost models, partner evidence and regional alignment statements before competitions open. This improves decision-making and reduces the risk of rushed, weak applications.
The UK struggles to turn discovery into growth because strong research does not automatically create scalable businesses. Commercialisation depends on capital, grant strategy, partnerships, procurement, skills, intellectual property planning and the ability to move from research promise to market evidence.
For CFOs, CEOs and innovation leaders, this is not just a policy debate. It affects where R&D budgets are allocated, how projects are financed and whether promising technologies can survive the difficult stage between proof of concept and commercial traction.
The UK has deep scientific capability, respected universities and strong public research institutions. The harder question is why too many discoveries still fail to become high-growth companies, exportable technologies or investable industrial assets.
Turning discovery into growth means moving a scientific, technical or research breakthrough into a product, process, service or platform that creates measurable economic value.
This usually involves more than proving that an idea works. A business must show that the technology can be developed, protected, funded, validated, scaled and adopted by customers or industrial partners.
A discovery may start in a university lab, corporate R&D team, clinical setting or engineering project. Growth begins when that discovery becomes investable and commercially usable.
This is where many promising UK projects lose momentum. The research may be strong, but the commercial pathway may be unclear, underfunded or poorly aligned with market demand.
The UK has a commercialisation gap because research quality is often stronger than the systems that help technologies scale. Businesses may lack patient capital, funding visibility, procurement routes, specialist talent or the internal capacity to manage complex innovation finance.
This gap is sometimes described as the problem of moving from lab to market. In practical terms, it often appears when a project reaches a point where grant funding, private investment and commercial evidence all need to line up.
Common pressure points include:
A technically credible project can still fail if the business case is not developed early enough.
This matters to CFOs and CEOs because commercialisation failure creates stranded R&D cost. The business may spend heavily on research, people and prototypes without building the evidence needed to secure follow-on funding or commercial adoption.
The finance question is not simply whether the project is innovative. It is whether the project has a realistic funding pathway from early-stage research through to deployment.
For leadership teams, that means asking:
A discovery-led business needs financial control as much as technical ambition. Without this, promising work can become an expensive internal experiment rather than a platform for growth.
Businesses usually get stuck between technical validation and commercial readiness. This is where project costs rise, evidence standards increase and funders expect a clearer route to market.
The early phase of innovation is often easier to justify internally. The business can frame the work as exploratory research or technical feasibility. The difficult phase comes when leadership must decide whether to fund prototypes, testing, regulatory work, customer trials or scale-up infrastructure.
| Commercialisation challenge | What it means for the business |
| Weak market evidence | The project solves a technical problem, but demand is not proven |
| Unclear funding route | The business relies on one grant or one investor conversation |
| Poor cost mapping | Finance teams cannot separate eligible R&D, grant-funded work and commercial expenditure |
| Late IP planning | Ownership, licensing or exploitation rights are not clear enough |
| No procurement pathway | Public or private customers are interested, but adoption routes are slow |
| Underdeveloped partnerships | The company lacks academic, industrial or supply chain support |
| Short funding runway | The project cannot survive the period between validation and revenue |
The best commercialisation strategies deal with these issues before the next funding deadline or investment round.
Businesses can make discovery more investable by turning technical progress into commercial evidence. Funders and investors need to see why the project matters, who will use it, how it will scale and what makes the company capable of delivery.
This requires a different mindset from pure research. A strong project should be able to explain:
Grants can help businesses bridge the commercialisation gap by supporting defined innovation work before private finance is ready to carry the full risk. They are particularly useful for feasibility, collaborative R&D, prototype development, demonstration and early-stage scale-up.
However, grants are not a substitute for strategy. A business should not chase competitions simply because they are open. The strongest grant strategy starts with the company’s project pipeline, not the funder’s deadline.
A grant-ready project usually has:
This is where many companies underperform. They describe the invention well, but not the adoption case. Funders need to know what changes if the project succeeds.
R&D tax relief can support discovery-led companies by recognising qualifying expenditure on eligible R&D activities. It is most useful when the business has clear records of scientific or technological uncertainty, qualifying costs and project-level evidence.
R&D tax relief should not be treated separately from commercialisation planning. It sits inside the wider innovation finance picture.
For example, a business may use grants to support a future R&D project while also claiming R&D tax relief for qualifying expenditure in the relevant accounting period. Where grants are involved, the interaction needs to be managed carefully.
CFOs should maintain clear records showing:
This reduces later friction and helps the finance team understand the true net cost of innovation.
CFOs should build a discovery-to-growth funding plan by mapping projects against maturity, cost, risk and funding route. The aim is to avoid a single-point dependency on one grant, one investor or one internal budget line.
A practical plan should cover five stages:
At this stage, the company should define the technical problem, identify uncertainties and test whether the project has commercial relevance. Potential support may include feasibility grants, internal R&D budgets and R&D tax relief for qualifying activity.
The business should create evidence that the technology can work in a relevant environment. This may involve testing, data collection, partner input or customer discovery. Grant funding can be useful here, especially where public benefit, collaboration or sector priority is clear.
The project needs to show that the innovation can operate beyond a controlled research setting. Demonstrators can be expensive, so cost planning and partner alignment matter.
This is where capital intensity can rise quickly. Manufacturing, regulatory work, clinical validation, infrastructure, certification or production engineering may all create funding pressure.
At this stage, the key issue is adoption. Businesses need customers, procurement routes, distribution channels, regulatory confidence and operational delivery.
UK discoveries often compete in global markets from the start. A strong commercialisation plan should consider international funding, overseas R&D incentives, European collaboration and market-entry requirements.
For businesses operating across borders, the funding picture can become complex. A project may involve UK R&D teams, EU collaborators, overseas testing, international customers or group-level IP structures.
This is where a single-country view can limit growth. A company may need to understand how UK R&D tax relief, Innovate UK grants, Horizon Europe, Eurostars, EIC funding, regional incentives and overseas tax incentives interact.
FI Group by EPSA’s international position is relevant here. The firm supports companies across multiple jurisdictions, helping leadership teams connect local delivery with group-level innovation strategy. For CFOs and group executives, that matters because commercialisation rarely stops at the UK border.
A good discovery-to-growth strategy connects technical ambition with evidence, funding and execution. It gives the business a clear view of what must be proven, when funding is needed and which route is most credible.
A strong strategy usually includes:
This is the practical answer to the UK’s discovery-to-growth challenge. The issue is not a shortage of ideas. The issue is whether businesses can finance, evidence and execute them through the difficult middle stages.
The UK struggles to commercialise research because world-class discovery does not automatically create scalable companies. Businesses need capital, commercial evidence, grant strategy, IP planning, partnerships, customer validation and leadership capacity to move from technical promise to market adoption.
The discovery-to-growth gap is the space between proving a technical idea and turning it into a commercial product, process or service. It often involves funding pressure, market validation, regulatory work, scale-up costs and evidence requirements.
Grants can support defined innovation work such as feasibility studies, collaborative R&D, prototype development and demonstration projects. They help reduce risk before private investment or customer revenue is ready to support the full cost.
R&D tax relief can support qualifying R&D activity where a business is seeking to resolve scientific or technological uncertainty. It does not fund commercialisation directly, but it can improve the overall funding position for eligible R&D projects.
CFOs should check technical eligibility, commercial need, project costs, funding routes, evidence requirements, IP ownership, partner roles and likely follow-on funding. They should also consider how grants and R&D tax relief interact.
A fundable innovation project has a clear technical challenge, a credible delivery plan, strong market evidence, realistic costs, capable partners and a defined route to impact. Funders need to understand both the innovation and the commercial pathway.
Science-intensive businesses often face long development timelines, high technical risk, regulatory hurdles, specialist skills needs and capital-intensive scale-up. These factors can make the gap between research and revenue longer than expected.
No. Businesses should prioritise grants that fit their project stage, technology readiness level, sector, location, costs and commercial aims. A poor-fit application can waste management time and reduce focus on better funding opportunities.
For many first-time claimants, Advance Assurance can be useful, but only in a narrow set of cases. It helps eligible small companies reduce uncertainty before a first claim, but it does not replace claim notification, the Additional Information Form, or the need for a robust technical and financial filing.
If you are a cautious CFO, Finance Director, or founder preparing a first R&D tax relief claim, the real question is not simply whether Advance Assurance exists. The real question is whether it is the right certainty tool for your company, your timeline, and your claim risk.
This matters more now because HMRC’s compliance environment has changed. First claims are under greater scrutiny, structured reporting now sits earlier in the process, and HMRC is actively exploring broader assurance and pre-clearance routes. That makes Advance Assurance relevant again, but not always decisive.
Advance Assurance is a voluntary HMRC process that can give certain first-time SME claimants confidence that their first claims will be accepted if they match what HMRC reviewed. It is designed to reduce uncertainty before the claim is filed.
In practical terms, Advance Assurance lets an eligible company share details of its R&D work with HMRC before claiming relief through its CT600. If HMRC agrees that the relief applies, the company receives an agreement that covers its first three accounting periods, provided the claims stay in line with what was discussed and agreed.
That sounds attractive, especially to boards that want certainty before investing internal time in a new claim process. But it is important to understand what Advance Assurance is not:
Yes, if you are eligible and uncertainty is the main reason you are hesitating. No, if you are using it as a substitute for a well-prepared first claim.
The right answer depends on your situation. For some businesses, Advance Assurance is a sensible first step because it gives management comfort and helps unlock a claim that would otherwise be delayed. For others, it creates extra process without solving the real issue, which is usually weak technical framing, unclear cost treatment, or a lack of claim-readiness.
A simple decision rule is this:
Situation |
Advance Assurance likely to help? |
Why |
| Small first-time claimant, eligible, management wants early certainty | Yes | It can reduce hesitation and create confidence before filing |
| First-time claimant, but not eligible due to size or group history | No | You cannot use the scheme |
| Company already ready to file with strong evidence and clear methodology | Maybe not | The extra step may add friction rather than value |
| Business wants certainty on a complex issue outside the current narrow route | Not usually | The current route is limited and not a bespoke pre-clearance service |
| Board is worried about enquiry risk but the claim process is weak | No, not on its own | The bigger issue is evidence, governance, and technical quality |
Advance Assurance is aimed at first-time SME claimants with turnover below £2 million and fewer than 50 employees. If you fall outside those criteria, it is generally not the right route.
At the time of writing, HMRC’s current guidance is focused on smaller first-time claimants. That means you are broadly looking at a company that:
This matters because many businesses searching for “R&D pre-clearance” assume the option is open to all claimants. It is not. For many scaling businesses, software companies, PE-backed groups, and more mature claimants, the issue is not whether Advance Assurance is desirable. It is that the current route may not be available.
Advance Assurance sits alongside the first-claim process. It does not replace the mandatory steps that HMRC now expects before a valid claim is submitted.
This is where many first-time claimants get confused. The process now has more moving parts than it did a few years ago, and boards often treat them as interchangeable. They are not.
Step |
What it does |
Is it still needed if you use Advance Assurance? |
| Claim Notification Form | Tells HMRC you intend to claim, if required | Yes |
| Advance Assurance | Gives eligible first-time SMEs early confidence | Optional |
| Additional Information Form | Provides project and cost detail before filing | Yes |
| CT600 claim | Formally submits the relief claim | Yes |
This is why a purely “do we qualify?” article is no longer enough. The CFO audience needs to understand workflow risk. A company can be technically eligible for relief and still fail the process if it misses claim notification deadlines, submits the AIF late, or files the CT600 before the AIF.
Advance Assurance helps most when confidence, not capability, is the barrier.
There are several circumstances where it can be commercially sensible:
If the finance team or leadership group is worried that a first claim could trigger avoidable compliance issues, Advance Assurance can reduce psychological resistance and move the project forward.
For early-stage and smaller SMEs, especially those without an internal tax function, the scheme can be a useful bridge between “we think we qualify” and “we are comfortable filing”.
For cash-sensitive businesses, a first claim is often about more than tax. It can support runway, hiring, or investor messaging. In that context, additional certainty can be valuable if it prevents internal delays.
Some companies use the process to force early discipline around project selection, technical explanation, and cost mapping. Done properly, that can strengthen all three of the first covered periods.
Advance Assurance does not help when the real issue is claim quality, not claim confidence.
That distinction is critical.
If your baseline, technological uncertainty, or advance is poorly framed, the problem is not the lack of assurance. The problem is the claim itself.
You still need to get the timing, forms, and scheme treatment right. A company can receive assurance and still create downstream issues if it mishandles claim notification, AIF sequencing, subsidy treatment, or qualifying expenditure.
Many CFOs imagine a process where HMRC clears the whole claim strategy in advance. That is not how the current route works. It is narrower, more specific, and more restricted in who can use it.
If you have good evidence, strong project narratives, correct scheme treatment, and a disciplined filing process, the additional step may add delay without adding much practical value.
It can reduce risk for eligible companies if the final claim stays aligned to what HMRC agreed, but it is not a blanket shield against weak filing practice.
This is where nuanced positioning matters.
Advance Assurance can give a legitimate first-time claimant useful comfort. But enquiry risk is not created by one factor alone. Risk is shaped by the quality of your technical explanation, the traceability of your costs, the consistency of your story across forms, and the evidence behind the numbers.
The safest first claim is built on evidence, governance, and period-correct filing, whether or not Advance Assurance is used.
For most first-time claimants, that means building a simple but robust claim-readiness pack before submission:
This is also the right place to challenge a common mistake in the market. Many businesses treat first claims as exploratory and low-stakes. In reality, first claims often set the tone for future claims, future evidence expectations, and future interactions with HMRC.
HMRC is actively exploring wider assurance and advance clearance routes, so the topic is becoming more important, not less.
The policy direction matters here. HMRC consulted on broader R&D tax relief advance clearances in 2025, looking at how a more developed assurance model could reduce error, improve customer experience, and give businesses more certainty earlier in the process. The consultation has now concluded, and a targeted pilot is due to launch in Spring 2026.
That does not mean the answer for every business is to wait for a new service. It means finance leaders should recognise that pre-assessment is becoming part of the strategic conversation. Companies that build stronger evidence and governance now will be better placed whatever assurance routes expand next.
The UK is not alone in moving towards earlier scrutiny and pre-approval logic. Many jurisdictions already use pre-approval, registration, or advance-finding style processes for innovation incentives.
For multinational groups, this matters because tax certainty is becoming more front-loaded. The UK consultation itself pointed to a wide range of international models where companies must register, seek pre-approval, or obtain a technical finding before or alongside claiming relief.
This is where FI Group by EPSA brings a stronger value proposition than a single-jurisdiction filing provider. We help finance leaders connect Global Reach. Local Expertise. across jurisdictions, aligning local claim mechanics with central governance, documentation discipline, and cross-border risk management.
If your UK entity is making a first claim today, that may seem like a local issue. In practice, it often becomes the template for how the wider group thinks about innovation incentives, evidence, and advisory quality.
FI Group by EPSA is not a commoditised filing service. We support CFOs, founders, and technical teams with evidence-led claim strategy, clear process design, and advisory depth that holds up under a tougher compliance environment.
We help businesses:
For first-time claimants, the value is not just in filing a claim. It is in filing a claim that is worth repeating.
If you are preparing a first R&D tax relief claim and want to know whether Advance Assurance is worth pursuing, FI Group by EPSA can help you make the decision clearly.
We can assess your eligibility, review how Advance Assurance fits your timeline, and strengthen the wider claim process around claim notification, AIF preparation, technical narratives, and cost support.
Talk to FI Group by EPSA about building a first claim that is accurate, defensible, and board-ready.
First-time claimants often have the same concern: they want certainty, but they do not want to create extra process that slows the claim down. The FAQs below answer the most common questions CFOs, founders, and finance teams ask when deciding whether Advance Assurance is worth using.
No. Advance Assurance is voluntary. Eligible companies can choose to apply, but they can still make an R&D tax relief claim through the normal process if they do not use it.
No. If claim notification applies to your accounting period, you still need to complete that step even if you apply for Advance Assurance.
No. You still need to submit the Additional Information Form before, or on the same day as, your CT600 claim.
If successful, the agreement can cover your first three accounting periods, provided the claims remain consistent with what HMRC agreed.
Not under the current narrow route. It is aimed at certain smaller first-time SME claimants.
Miss the Claim Notification Form deadline and the technical quality of your R&D claim may stop mattering. For first-time and lapsed claimants, the filing position can be simple: notify HMRC in time, or lose the claim for that period. The form is separate from the Additional Information Form and the CT600.
Finance teams also need to look at the timing risk in context. HMRC says it checked 17% of claims in 2023 to 2024, the average compliance check took 246 days, and 77% of settled checks required an adjustment. That is a cash flow issue, a governance issue, and a workload issue.
The Claim Notification Form is HMRC’s advance notice requirement for certain companies intending to claim R&D tax relief. It is not the claim itself, and it does not replace the Additional Information Form or the Company Tax Return.
The rule sits inside the reformed R&D claims process introduced after the Finance (No. 2) Act 2023. HMRC’s internal manual ties the claims process to the Corporation Tax Act 2009, and the 2023 Regulations set out the information that must be included in a claim notification.
You usually need to submit a Claim Notification Form if you are claiming R&D tax relief for the first time, or if your last claim was made more than three years before the last day of the claim notification period.
In practice, that usually catches:
HMRC also lists two published exceptions where a previous claim does not remove the need to notify:
There is one further point that matters. If the actual R&D claim reaches HMRC by the last day of the claim notification period, that can remove the need for a separate form. Many companies miss that detail, then leave the work too late for it to help them.
Scenario |
Claim Notification Form needed? |
| First-ever R&D claim | Yes |
| Recent valid claim inside the three-year lookback, with no exceptions | Usually no |
| Previous R&D claim removed by HMRC from the return | Yes |
| Previous claim for a pre-1 April 2023 period made by amendment received on or after 1 April 2023 | Often yes |
| Long period of account covering more than one accounting period | One notification can cover the period of account, if notification is needed |
The detail still needs to be checked against the company’s own dates and filing history.
The deadline is the end of the “claim notification period”, which runs from the first day of the period of account to six months after the end of that period of account. Miss that deadline and the R&D claim can be invalid.
This is where many finance teams trip up. HMRC does not ask you to look only at the accounting period on the CT600. You also need to understand the period of account used in the financial statements.
For many businesses with a normal 12-month year end, the timing is straightforward. If your period of account ends on 31 March 2025, the last date to notify is 30 September 2025.
For long periods of account exceeding 12 months, the position is more technical. A single period of account can contain two accounting periods for Corporation Tax, but HMRC applies the same claim notification period across those accounting periods. That means one timely notification can cover the accounting periods falling within that same period of account.
| Scenario | Does the company need to notify? | Practical deadline |
| First-ever R&D claim, year end 31 March 2025 | Yes | 30 September 2025 |
| Claimed recently within the relevant three-year window | Usually no | No separate notification needed |
| Last valid claim was too old to fall within the lookback | Yes, unless the actual claim is filed by the last date of the claim notification period | Six months after period of account end |
| 18-month period of account with two CT accounting periods | Often yes for first-time or lapsed claimants, but one notification can cover both periods in that same period of account | Six months after the end of the full period of account |
These examples apply HMRC’s current timing rules and are useful for internal planning, but finance teams should still map the exact dates against the company’s own year-end structure.
A company does not usually need to submit the form if it has made an R&D claim within the three years ending with the last day of the claim notification period, unless one of HMRC’s stated exceptions applies.
There is another important nuance. If a company needs to notify, it can still avoid a separate notification form if the actual R&D claim itself is received by HMRC on or before the last date of the claim notification period. In other words, the claim can sometimes satisfy the timing requirement if it is filed early enough.
That point is valuable for CFOs because it turns the issue into a timetable question, not just a tax technicality. If your finance team will not have the technical narrative, cost schedules, and governance approvals ready early, you should not assume the claim can simply be accelerated to solve the problem.
HMRC’s internal manual, updated in March 2026, records an administrative easement for certain companies affected by incorrect HMRC guidance published between September and October 2024. The easement is narrow and fact-specific, so it should not be treated as a general safety net.
The Claim Notification Form, if required, comes first. The Additional Information Form must then be filed before, or on the same day as, the CT600 claim. Missing either step can invalidate the R&D claim.
For most claimants, the filing sequence should look like this:
This is why finance leaders should treat claim notification as part of claim governance, not as a minor admin step. The technical narrative might be excellent, but the claim can still fail on process.
The biggest mistakes are timing errors, filing sequence errors, and overconfidence in old processes. In the current compliance environment, those mistakes can create cash flow delays, management distraction, and a harder path for future claims.
The most common issues are:
This is the classic deadline error. Teams look at the CT600 period but forget the statutory deadline is tied to the period of account.
The exemption is not a vague “we claimed once before”. It is a specific three-year lookback test, with published exceptions.
HMRC’s guidance is explicit. If the AIF is filed after the return, the R&D claim can be rejected.
The form is only an early notice. The real evidential burden still sits in the AIF, the CT600, and the supporting technical and financial records.
For CFOs, this is where process risk becomes business risk. HMRC’s own 2023 to 2024 figures show both higher compliance coverage and long resolution times, which means poor filing discipline can turn into a serious cash flow issue.
A good process starts early, has named internal ownership, and leaves enough time between each filing step. It does not rely on year-end guesswork.
A practical checklist for finance teams:
The Claim Notification Form is not just a tax form. It is an early control point in the wider governance of your R&D claim. If you miss it, the problem is binary. If you get it right, you still need the AIF, CT600 accuracy, and evidence stack behind the claim.
For finance leaders, the real issue is predictability:
That is why this topic should be owned as part of the annual compliance calendar, not parked until the tax return is nearly ready.
The UK still relies mainly on notification plus post-claim checking, but the policy direction is moving towards more targeted pre-claim assurance. HMRC concluded its consultation on R&D tax relief advance clearances and says it will launch a limited pilot of a new targeted advance assurance service in Spring 2026, while the existing advance assurance offer continues.
That matters for multinational and internationally ambitious groups. HMRC’s consultation notes that many countries already use some form of pre-approval or advance assurance, while the UK is exploring a more targeted model. HMRC also notes that its current advance assurance process has had very low uptake.
For UK groups with overseas operations, the wider lesson is clear: R&D incentives are becoming more process-driven, more evidence-led, and more front-loaded. FI Group by EPSA’s value in that environment is the ability to align HQ strategy with local filing rules, so your UK claim notification, AIF, and wider international governance all work together.
FI Group by EPSA helps CFOs and finance teams turn R&D tax relief from a reactive filing exercise into a controlled process.
We support clients by:
That is where Global Reach. Local Expertise. becomes practical, not just promotional. One group standard, applied properly to the UK rules.
This section answers the questions finance teams most often ask when planning an R&D claim.
Yes. “Advanced Notification Form” or ANF is common market shorthand, but HMRC’s current guidance uses Claim Notification Form.
No. You usually only need it if you are a first-time claimant or your last qualifying claim falls outside the relevant three-year lookback, subject to HMRC’s exceptions.
Yes. HMRC says the form can be submitted by a company representative or an authorised agent.
Not always. HMRC says the actual R&D claim can satisfy the timing requirement if it is received by the last date of the claim notification period.
Yes, where those accounting periods fall within the same period of account, the claim notification period is the same.
No. The Claim Notification Form is an advance notice requirement for certain claimants. The AIF is the detailed information HMRC requires before or alongside the claim itself.
HMRC’s guidance says the R&D claim can be rejected if the AIF is filed after the return.
No. Advance assurance is a separate voluntary HMRC process. The current public guidance says it is aimed at first-time SME claimants below certain size thresholds, and HMRC is also developing a more targeted pilot.
Yes. HMRC’s manuals were updated in March 2026, and HMRC has also confirmed a targeted advance assurance pilot is due to launch in Spring 2026.
Build the claim timetable backwards from the period of account end date, check notification status early, prepare the AIF before the CT600, and do not rely on prior filing habits.
In an R&D claim, the competent professional is the person whose technical judgement helps establish whether the work sought a genuine advance in science or technology, whether scientific or technological uncertainty existed, and where the qualifying R&D began and ended. If that judgement is weak, the whole claim becomes harder to defend.
For many businesses, this is where the claim either becomes clear and credible or vague and exposed. The role is not administrative. It goes to the centre of how qualifying R&D is assessed.
A competent professional is someone with the right qualifications or practical experience in the relevant field to judge whether a project sought an advance in science or technology and whether the answer was not readily deducible at the outset.
This is not just a question of seniority. A founder, CTO, technical director or lead engineer may be the right person, but title alone does not decide it. The real test is whether that person can explain:
That matters because HMRC does not assess a project against what was new to your business. It looks at what was known, or could readily be worked out, by a competent professional working in the field.
The competent professional matters because the core R&D test depends on expert technical judgement.
A claim needs someone who can explain why the project involved more than routine development, routine engineering, or ordinary problem-solving. That person should be able to show why the uncertainty was genuine, why the solution was not obvious at the outset, and why the work represented an advance in the field rather than only an internal improvement for the company.
This is also why weak claims often struggle. They may describe a complex commercial project, but they do not explain the underlying scientific or technological uncertainty clearly enough. Without a credible technical voice behind the narrative, the claim can drift into general business description rather than a defensible R&D position.
The competent professional can be internal or external, provided they have the right technical depth in the field that matters for the project.
In practice, that may be:
What matters is fit. If the project concerns embedded systems, complex software architecture, novel materials, process engineering, data infrastructure or medtech development, the competent professional should have genuine expertise in that area.
The wrong choice is often obvious in hindsight. A commercially senior person may know the business extremely well, but still be the wrong person to judge the underlying scientific or technological question.
The competent professional should help define four things clearly:
Question |
What the claim should show |
| What was the baseline? | What was already known or readily deducible in the field |
| What was the advance? | The improvement in science or technology being sought |
| What was the uncertainty? | Why the answer was not readily available at the start |
| Where did the R&D begin and end? | Which activities directly contributed to resolving that uncertainty |
This point is important because not every activity in a wider commercial project qualifies. A project may include concept design, trials, testing, scale-up, implementation, quality assurance, commercial deployment and customer support. Only some of those stages may involve qualifying R&D.
The competent professional helps identify the boundary properly. That creates a stronger technical narrative and usually supports better cost discipline too.
This is one of the most important distinctions in an R&D claim.
A technical challenge may be difficult, expensive, time-sensitive or commercially important. That does not automatically make it qualifying R&D.
A technological uncertainty exists where it is not readily deducible by a competent professional whether something is scientifically or technologically possible, or how it can be achieved in practice.
That is why businesses sometimes overstate qualifying activity. A project can involve real pressure, ambitious targets and demanding delivery work without meeting the R&D test. The issue is not how hard the work felt internally. The issue is whether the scientific or technological answer was genuinely uncertain at the outset.
No, but they should shape the technical case early and review it properly before submission.
Finance teams and advisers can structure the claim, prepare the cost analysis and assemble the filing. But the technical core should come from the person best placed to judge the advance and the uncertainty.
Where businesses often go wrong is timing. They draft a broad narrative first, then ask the technical lead to approve it at the end. That usually produces weak language, blurred boundaries and generic explanations.
A stronger process starts with the technical conversation. The competent professional should help define:
A name on a form is not enough. The claim should make clear why that person was the right person to judge the project.
Useful evidence may include:
That evidence does not need to dominate the page, but it should support the credibility of the technical narrative. A strong claim shows both the substance of the uncertainty and the credibility of the person explaining it.
Yes, but that does not remove the need for internal accountability. HMRC says the competent professional may be external. In some cases that is the best option, especially where the company lacks depth in-house.
At the same time, HMRC’s claims process still places responsibility on the claimant company. Where a claim notification is required, HMRC asks for the main senior internal R&D contact responsible for the claim. For the Additional Information Form, HMRC also expects project descriptions that explain the uncertainties and the activities used to resolve them, and it allows a separate report with more detail on methodology and competent professionals.
The practical answer is usually a blend. Internal technical owners provide project reality. Specialist advisers help turn that into a cleaner, more defensible claim.
The most common errors are usually straightforward.
Some companies default to the most senior person in the business. Others default to whoever signs off the claim. Neither approach is reliable. The competent professional should be chosen because of field-specific technical depth.
A weak claim often compares the project against what the company knew internally, rather than what was already known in the field. That makes ordinary development work sound more novel than it really was.
A project may be complex, expensive or commercially risky without involving qualifying R&D. The claim needs to show genuine scientific or technological uncertainty, not just a demanding delivery environment.
If the technical lead only sees the draft at the end, important detail is often missed. Baseline, uncertainty and project boundaries should be set early.
Phrases such as “complex project”, “significant challenge” or “innovative solution” do not carry enough weight on their own. The claim should say what was uncertain, why it was uncertain, and what work addressed it.
In software claims, the competent professional is often a senior architect, engineering lead or principal developer. The claim should explain why the uncertainty related to architecture, integration, performance, scalability, security or system behaviour, rather than standard development work.
In engineering claims, the competent professional may be a lead design engineer, process engineer or technical director. The narrative should show what was already known in the field, what constraints applied, and why the answer could not readily be worked out at the start.
In life sciences, the competent professional is often a senior scientist, formulation lead, technical director or specialist consultant. The claim needs to distinguish genuine scientific or technological uncertainty from regulatory, commercial or operational hurdles.
For leadership teams, the competent professional question is really about claim quality, governance and resilience.
If the technical ownership is weak, three problems usually follow:
That is why this issue matters beyond tax compliance. It affects cash flow, internal effort and confidence in the wider R&D claim process.
While the phrase competent professional is specific to UK R&D tax language, the underlying issue is broader. International groups still need the right technical decision-makers, consistent evidence standards and a clear link between technical work and claim preparation.
For businesses operating across multiple jurisdictions, that means balancing local technical depth with wider group-level governance. FI Group by EPSA supports clients through a model that combines global reach with local expertise, helping businesses align technical evidence with country-specific requirements while maintaining a clearer overall funding and innovation strategy.
FI Group by EPSA helps businesses identify the right competent professional, frame the baseline correctly, and build stronger technical narratives around qualifying R&D.
That can include:
If your business is carrying out genuine R&D but your claim still relies on broad project summaries, FI Group by EPSA can help turn technical complexity into a clearer, more defensible filing.
No. The role depends on technical competence in the relevant field, not board status.
Yes, if the CTO has the right technical depth in the field and can judge the baseline, the advance and the scientific or technological uncertainty.
Yes. An external expert may be appropriate where the company does not have enough in-house technical depth.
No. Different projects may require different specialists depending on the field and the uncertainty involved.
Not necessarily, but their judgement should shape the technical case and the way qualifying projects are described.
Useful records may include design notes, test results, technical meeting notes, failed attempts, prototype evidence and documents showing how the uncertainty was addressed.
Yes. Software projects still need someone qualified to judge whether scientific or technological uncertainty existed.
That may still be a genuine technical challenge for the business, but it is less likely to meet the R&D tax definition.
Ideally at the start of claim preparation, while project scoping and technical interviews are still underway.
Quantum funding in 2026 is no longer a single story. The UK’s ten-year £2.5 billion quantum strategy still sets the long-term direction, but the near-term picture is now much clearer: more emphasis on mission-led adoption, commercialisation infrastructure, and real-world deployment. That direction was reinforced again on 17 March 2026, when the government announced a fresh quantum package worth up to £2 billion focused on scaling capability and deployment.
Key points at a glance
The UK’s five quantum missions make the policy direction easier to read than it was a year ago. Two of those missions are long-range, with 2035 goals around computing and networking. Three are closer-term, with 2030 goals tied to healthcare sensing, resilient navigation and mobile sensing for critical infrastructure. That matters because it shows where government wants adoption to happen first.
The funding pattern now broadly matches those missions. Innovate UK’s November 2025 quantum awards put more than £14 million into 14 projects, with a clear emphasis on sensing and quantum-enabled position, navigation and timing rather than a narrow computing-only story.
No. Quantum computing remains a core national priority, but the funding architecture is broader than that.
Mission 1 still targets accessible UK-based quantum computers capable of running 1 trillion operations by 2035, while Mission 2 targets a quantum network at scale by the same date. But Missions 3, 4 and 5 show equal policy intent around adoption in healthcare, aircraft navigation and critical infrastructure. In other words, quantum funding in 2026 is increasingly split between long-horizon computing capability and nearer-term deployment use cases.
That broader approach is also visible in government announcements. The April 2025 £121 million quantum package focused on applications including fraud prevention, healthcare and energy efficiency, while the March 2026 package moved further towards rollout at scale.
Quantum sensing is one of the strongest short-term funding themes. Mission 3 aims for every NHS Trust to benefit from quantum sensing-enabled solutions by 2030, while Mission 5 targets mobile, networked quantum sensors across transport, telecoms, energy and defence. That makes sensing one of the clearest lanes for businesses with application-led propositions.
PNT is another strong lane. Mission 4 is explicit that by 2030 quantum navigation systems, including clocks, should be deployed on aircraft. In practice, that frames PNT as an infrastructure resilience issue, not just a laboratory advance. Businesses working on GNSS resilience, precision timing and navigation applications are now much easier to map against a visible public priority.
Quantum networking is still strategically important, but it reads more as a scale-building and infrastructure play than an immediate mass-adoption market. Mission 2 is about nationwide connectivity, early commercialisation, standards leadership and international collaboration, which points to a slower but still very important funding lane.
A major shift in the funding landscape is that support is no longer just about single project awards. It is increasingly about translation environments.
In February 2024, UKRI and the National Quantum Computing Centre invested £30 million in quantum computing testbeds. In November 2025, the Harwell Quantum Cluster launched with the aim of creating more than 1,000 high-value jobs and bringing £1 billion of investment into the UK over the next decade. Alongside that, the Commercialising Quantum Technologies Challenge invested more than £174 million, backed by more than £390 million from industry, between 2018 and 2025. Together, those signals point to a more mature commercialisation model: not just grants for invention, but infrastructure for scaling, testing and attracting private capital.
As of 27 March 2026, these are some of the most relevant routes for quantum businesses:
For quantum businesses trying to turn technical progress into a workable funding strategy, FI Group by EPSA can help align grant opportunities, collaborative programmes and wider non-dilutive incentives with commercial milestones, evidence requirements and application timing.
The clearest near-term signals point to quantum sensing, quantum-enabled PNT and infrastructure-led applications, based on the UK missions and recent Innovate UK awards.
Yes. Quantum computing remains central to UK strategy, with Mission 1 targeting UK-based quantum computers capable of 1 trillion operations by 2035, supported by testbeds, NQCC activity and more recent government backing for rollout at scale.
Yes. One of the most visible current routes is the UK-Germany Collaborative Innovation for Quantum Technologies 2026 competition, which offers up to £3 million and closes on 15 April 2026.
Yes. UK researchers and businesses have wider access to Horizon Europe quantum calls, and the 2026 digital work programme includes several quantum-relevant topics.
Because they bridge the gap between research capability and commercial readiness. In practice, they help businesses compare approaches, refine applications and move closer to market adoption.
